Outcome and Toxicity Patterns in Children and Adolescents with Non-Hodgkin Lymphoma: A Single Institution Experience

Paola Angelini1*, Laura Rodriguez2*, Mohammed Zolaly3, Ahmed Naqvı4, Sheila Weitzman4, Oussama Abla4 and Angela Punnett4.

1 Paediatric Oncology Unit, The Royal Marsden NHS Foundation Trust, Sutton, UK.
2 Canadian Cancer Trials Group, Queen's University, Kingston, ON, Canada.
3 Department of Pediatrics, Faculty of Medicine, Taibah University, Al-Madinah Al-Munawwarah, Saudi Arabia
4 Department of Pediatrics, Division of Haematology and Oncology, The Hospital for Sick Children, Toronto, Canada.

Competing interests: The authors have declared that no competing interests exist.

Abstract. Background: The incidence and biology of non-Hodgkin lymphoma (NHL) vary according to age. Some data suggest that the impact of age in pediatric and adolescent NHL patients depends on the histological subtype. Objectives: We aimed to analyze the impact of age at diagnosis on clinical characteristics and treatment-related toxicity in children and adolescents with NHL.

Methods: Retrospective review of medical records of children and adolescents diagnosed with NHL at the Hospital for Sick Children, Toronto, between January 1995 and December 2008.

Results: 164 children were diagnosed with NHL during the study period, with a median age at diagnosis of 10 years. With a median follow-up of 6.2 years, 5-year OS in patients aged <15 and 15-18 years was 89% ± 2% vs 82% ± 6%, respectively (P = 0.30), and 5-year EFS was 84% ± 3% vs. 77% ± 7% (P= 0.37). In Burkitt's lymphoma (BL) and lymphoblastic lymphoma (LL) there was a trend towards better outcomes in children compared to adolescents, with EFS of 91% ± 4% vs. 75% ± 15%, respectively in BL (P= 0.17), and 82% ± 7% vs. 51.4% ± 2% respectively in LL (P= 0.16). Late effects occurred in 21 patients (12.8%).

Conclusions: Children with NHL aged < 15 years tend to have better survival rates and similar long-term toxicity than adolescents aged 15-18 years.

Keywords: Lymphoma, Age, Adolescents, Toxicity, Outcomes.

Citation: Angelini P, Rodriguez L, Zolaly M, Naqvı A, Weitzman S, Abla O, Punnett A. Outcome and toxicity patterns in children and adolescents with non-Hodgkin lymphoma: a single institution experience. Mediterr J Hematol Infect Dis 2018, 10(1): e2018020, DOI: http://dx.doi.org/10.4084/MJHID.2018.020

Published: March 1, 2018 Received: December 13, 2017 Accepted: February 2, 2018

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Correspondence to: Paola Angelini, Children and Young People Unit, The Royal Marsden NHS Foundation Trust. Address: Downs Road, Sutton SM2 5PT, United Kingdom. Tel: +44 (0)7982960354. Email: paola_angelini@yahoo.com

Introduction. Non-Hodgkin lymphoma (NHL) represents approximately 7% of all malignancies in children. The overall incidence of NHL increases with age, and the outcome differs amongst children being marginally less favourable in infants and adolescents.1-2 Over the last three decades, significant improvements have been achieved in the outcome of pediatric NHL with current survival rates ranging between 80 to over 90% in mature B-cell lymphomas,3 and only slightly lower in lymphoblastic lymphomas (LL)4 and anaplastic large cell lymphomas (ALCL).5 This is mostly due to treatment assignment on the basis of the histological subtype, cytogenetic abnormalities, and disease stage.6 Adolescents have been reported to have a poorer outcome

www.mjhid.org Mediterr J Hematol Infect Dis 2018; 10; e2018020
compared to children, particularly in some histological subtypes such as Burkitt’s lymphoma (BL). This survival difference remains only partially explained and the age cut-off itself, between children and adolescents, has been set at either 14 or 15 years in different studies. The aim of this retrospective study was to analyze the clinical characteristics and outcome of children with NHL treated at the Hospital for Sick Children in Toronto, Canada, and to determine whether children < 15 years of age have different clinical features, and/or outcomes than adolescents (age 15-18 years). The Hospital for Sick Children is a pediatric tertiary care center, therefore we provided all patients, including the teenagers, consistent care with pediatric protocols, and maximum enrollment into clinical trials when available, thus eliminating some of the issues which have been associated with poor outcomes in adolescents (treatment in adult centers, poor compliance, poor enrolment into clinical trials).

Materials and Methods. Research ethics approval was obtained from our institutional board. Medical records of children ≤ 18 years of age with newly diagnosed NHL admitted to the Hospital for Sick Children from January 1995 to December 2008 were retrospectively reviewed. Patients with human immunodeficiency virus infection, congenital immunodeficiency, previous organ transplantation, previous malignancy, previous chemotherapy or radiotherapy and those with a diagnosis of mycosis fungoides were excluded. NHL subtypes were classified according to 2001 WHO Classification of Haematological Malignancies. Disease staging was performed according to the St. Jude staging system including a physical examination, peripheral blood and bone marrow smears, cerebrospinal fluid (CSF) analyses, serum lactate dehydrogenase (LDH) levels and adequate imaging techniques. Patients with LL and ≥ 25% bone marrow (BM) blasts were diagnosed as acute lymphoblastic leukemia (ALL) and were excluded. Central nervous system (CNS) was considered positive at diagnosis if there were ≥ 5 lymphoma cells/µl in the CSF and/or cranial nerve palsy and/or cerebral lesions on neuroimaging. Lactate dehydrogenase (LDH) level was considered elevated if it was greater than twice the upper normal limit. B symptoms were defined as fever, drenching night sweats during the last six months, and weight loss at > 10% of baseline weight. Toxicity was graded as per CTCAE v4.

Therapy. Patients with T and B-cell LL received an ALL-type protocol consisting of a 4-drug induction (prednisone, vincristine, daunorubicin, asparaginase plus intrathecal methotrexate) therapy and consolidation (6-mercaptopurine, cyclophosphamide, cytarabine, prednisone and intrathecal methotrexate) therapy, followed by interim maintenance (high-dose methotrexate and intrathecal methotrexate), delayed intensification (dexamethasone, vincristine, doxorubicin, asparaginase, cyclophosphamide, cytarabine, thioguanine and intrathecal methotrexate) and maintenance therapy (oral 6-mercaptopurine and methotrexate plus monthly pulses of prednisone and vincristine) for a total therapy duration of 24 months. Patients with early-stage NHL including BL, diffuse large B-cell lymphoma (DLBCL), and ALCL were treated with the old POG9219 protocol consisting of CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) therapy plus intrathecal methotrexate for two months. When the studies were open to accrual, patients with advanced stage LL, mature B-NHL and ALCL were recruited to the COG protocols A5971, ANHL01P1 and ANHL 0131 respectively. Off study patients received the standard arm of the protocols.

Patients with advanced-stage BL and DLBCL received LMB-96 type regimens consisting of a reductive phase (cyclophosphamide, vincristine, prednisone and intrathecal methotrexate and hydrocortisone) followed by induction (vincristine, prednisone, cyclophosphamide, high-dose methotrexate with folic acid rescue and intrathecal methotrexate and hydrocortisone) therapy and consolidation (high-dose methotrexate with folic acid, intrathecal methotrexate, hydrocortisone and cytarabine for stage III patients); stage IV patients received a higher dose of methotrexate (8 grams/m²) in induction, high-dose cytarabine and etoposide in consolidation and four cycles of maintenance therapy. Patients with advanced ALCL received the APO regimen consisting of induction (doxorubicin, vincristine, prednisone and intrathecal methotrexate) therapy followed by consolidation (6-mercaptopurine, prednisone, vincristine, doxorubicin until a cumulative dose of 300 mg/m² which was later substituted by intravenous methotrexate) therapy
Patients were stratified according to their age at diagnosis into two groups: <15 (children) and 15-18 years of age (adolescents). The male to female ratio was 1.5:1, with no significant difference between the age groups. The most frequent site of involvement was head and neck in the <15 year-group and abdomen in the 15-18 year-group. Among all NHL patients, 76% presented with advanced-stage disease (stage III or IV), 15% with elevated LDH, 38% with B symptoms, 11% with BM involvement and 9% with CNS involvement, with no significant differences between the two age groups. BL was diagnosed in 52 patients (33%), ALCL in 48 patients (29%) (including 1 primary CNS lymphoma), LL in 43 patients (26%) and DLBCL in 15 patients (8%) (including 1 primary CNS lymphoma, and 2 primary mediastinal B-cell lymphomas) and peripheral T-cell lymphoma (PTCL) in 6 patients (4%). BL was the most frequent histological subtype among children, while ALCL was the commonest among adolescents. Among 48 patients with ALCL and available Alk-1 reactivity data, 87%, and 77% of children and adolescents were positive, respectively (Not Significant, NS). As expected, 88% of LL patients had a T- and 12% had B-precursor immunophenotype.

**Treatment outcome.** At a median follow-up of 6.2 years (range 0.1–15.7 years), the 5-year EFS for all patients was 82% ± 3% and the 5-year OS 88% ± 2%. EFS was comparable in children <15 years of age and adolescents (84% ± 3% vs. 77% ± 7%, \( P = 0.37 \)), as well as 5-year OS (89 ± 2% vs 82% ± 6%, \( P = 0.30 \) (Figure 1A)). When the patients were stratified by histological subtype, some trends became evident. Among BL patients, the 5-year EFS tended to be superior in children compared to adolescents (91% ± 4% vs 75% ± 15%, respectively; \( P = 0.17 \)). Similarly, children with LL had better EFS than adolescents (82% ±7% vs 51.4% ± 2%, \( P = 0.16 \) (Figure 1A).

**Results.**

**Patients’ characteristics.** From January 1995 to December 2008, a total of 164 immunocompetent children ≤ 18 years of age were diagnosed with NHL in our Institution. The median age at diagnosis was ten years (range, 1-17) (Table 1).

| \( N \) | Sex ratio | Age years (med., range) | LDH > 2 x ULN | Stage (%) | Site involvement (%) |
|---|---|---|---|---|---|
| | | | | I/II | II/I V | H/ N | P N | Medi ast | Lung | Abd | Bone | Skin | BM | CNS |
| | | | | | | | | | | | | | | | |
| BL | 52 | 3.3:1 | 8.5 (1-16) | 27 | 38 | 62 | 54 | 19 | 17 | 10 | 63 | 17 | 0 | 10 | 10 | 88.5 ± 4 | 90.4 ± 4 |
| DBCL | 15 | 0.9:1 | 11 (1-17) | 7 | 33 | 67 | 20 | 27 | 20 | 13 | 40 | 20 | 0 | 7 | 13 | 86.7 ± 8 | 93.3 ± 6 |
| PTCL | 6 | 5:1 | 11 (4-16) | 50 | 17 | 83 | 33 | 17 | 17 | 17 | 50 | 17 | 17 | 33 | 17 | 50 ± 20 | 83.3 ± 15 |
| LL | 43 | 1.6:1 | 7 (2-17) | 19 | 7 | 93 | 72 | 19 | 81 | 2 | 44 | 5 | 0 | 12 | 9 | 77.4 ± 6 | 84 ± 6 |
| ALCL | 48 | 0.8:1 | 12 (2-16) | 0 | 23 | 77 | 54 | 44 | 35 | 19 | 42 | 25 | 15 | 10 | 8 | 82.3 ± 5 | 87.3 ± 5 |
Figure 1A. OS and EFS by age. Figure 1B. EFS by age and histological subtype.

Among ALCL patients, 5-year EFS was comparable in children and adolescents (81.4 ± 7.6% and 87 ± 7% respectively, P= 0.68) (Figure 1B), irrespective of skin, mediastinum, lung, liver and spleen involvement. Among 6 PTCL patients, 5 children aged < 15 years are currently alive and disease free and the only adolescent died from treatment-related toxicity.

Overall, twenty patients (12.2%) relapsed, 7 in the primary site only (35%), 4 in CNS alone (20%), 3 in the bone marrow alone (15%), 1 in each of liver only, neck only and testicular only
developed late sequelae, versus 16 of 153 who did not (P < 0.05). Two BL survivors developed a second malignancy, a papillary thyroid carcinoma and a myelodysplastic syndrome, both among children <15 years of age, at 6 and 7 years since the end of treatment, respectively.

**Discussion.** Non-Hodgkin lymphoma is one of the most common cancers diagnosed among adolescents.\(^{11}\) Age has been shown to be of prognostic value in some histology subtypes, but the age threshold is not defined and varies in different histology subtypes. We chose to use 15 years of age as limit between children and adolescents, in line with SEER and ASH definition.\(^ {12}\)

Overall, the demographic characteristics of our patients do not deviate from the literature. Of note, ALCL was the second most common lymphoma and constitutes 29% of the cases in our series, higher than most of the literature data.\(^ {7,13-15}\) A possible explanation of these differences could be the racial diversity of our Canadian population. Further epidemiological studies on the incidence of lymphoma subtypes in populations of different ethnic background and on the pathogenesis of ALCL could improve our understanding.

We observed a significantly worse outcome among adolescents with BL, as previously reported by other authors.\(^ {17,18}\) In the NHL-BFM group, 5-year EFS was 88% in children compared to 82% in adolescents (P= 0.06).\(^ {6}\) However, in a more recent study on pediatric patients with mature B lineage NHL, the 3-year EFS was 89% and 84%, for patients <15 years versus > 15 years of age, respectively.\(^ {19}\) Differences in biology and genetics have been hypothesized to be responsible for this different outcome, but this question is still unanswered. Mbulaiteye *et al.* found that BL incidence may have trimodal incidence peaks, and concluded that BL peaking at different ages might have different etiology and/or biology.\(^ {20}\) Trautmann *et al.* reported age biased differences, with two gene rearrangements occurring almost exclusively in patients <14 years of age, and hypothesized that an antigen-driven selection might differ between pediatric and adult Burkitt’s lymphoma cases.\(^ {21}\) Other authors did not find significant differences between pediatric and adult BL with respect to immunophenotype, genomic aberrations or gene expression profiles.\(^ {22}\)

---

**Late effects.** Twenty-one patients (12.8%) developed late effects related to disease and/or treatment, with no significant differences between children and adolescents (Table 2). Patients who had undergone radiotherapy or HSCT (either autologous or allogeneic) were more likely to develop late effects. Six of 17 patients (35.3%) who had received radiotherapy developed late effects, versus 15 of 147 who did not (P < 0.05).

One had total body irradiation as part of HSCT conditioning regimen; five had cranial irradiation (4 as upfront treatment due to CNS involvement at diagnosis, one patient due to CNS relapse). Five of 11 patients (45.5%) who underwent HSCT

---

**Table 2**

| Late effect               | Total patients | < 15 year old | 15-18 year old |
|---------------------------|----------------|---------------|----------------|
| Neuro-cognitive           | 6              | 6             | 0              |
| Neurological              | 3              | 3             | 0              |
| GH deficiency             | 1              | 1             | 0              |
| Hypothyroidism            | 1              | 0             | 0              |
| Hypogonadism              | 4              | 3             | 1              |
| Hypertension              | 1              | 0             | 0              |
| Cardiac                   | 2              | 2             | 0              |
| Obesity                   | 4              | 3             | 1              |
| Diabetes insipidus        | 1              | 1             | 0              |
| Osteoporosis              | 2              | 2             | 0              |
| AVN                       | 2              | 1             | 1              |
| Kidney function           | 1              | 1             | 0              |
| Bronchiolitis obliterans  | 1              | 1             | 0              |
The addition of rituximab to the therapy of all mature B-NHL, based on the results of the recently closed international study, has proven beneficial both in children and adolescents. Our paper focuses on patients treated before the introduction of rituximab, to have a homogenous population, and therefore does not contribute information in this respect.

We observed a trend towards an inferior outcome for adolescents with LL. This has also been reported previously. Termuhlen et al., reported that among patients with advanced stage LL, age <10 years was associated with improved outcomes (P < 0.001). The CCG502 trial reported an increased relative risk of treatment failure of 2.7 for the 38 patients >14 years of age compared with 156 patients <10 years of age at diagnosis (P= 0.008). Similar results were reported by the BFM.

In this report, there was no difference in outcome related to age in ALCL, which is similar to the literature data. Although not significant, the finding of an increased incidence of ALK1-negative ALCL in the adolescent group is in keeping with other reports.

Regarding outcomes, patients <15 years experienced more treatment-related complications but had slightly lower treatment-related mortality.

The long-term toxicities including second malignancies were lower than expected explained by the combination of short follow up time in some patients and the use of newer treatment regimens designed to maintain survival while reducing long-term morbidity.

Our series presents some limitations. While the advantage of a single institutional series lies in the homogeneous radiological and pathological assessment, the limitation is in the small size of the study population. We decided to use the WHO 2001 classification, as using the 2008 revised version would have led to further dividing into subgroups too small to allow any statistical analysis. As well, being a pediatric tertiary care center, we provided all patients, including the teenagers, consistent care with pediatric protocols, maximum enrollment into clinical trials when available, thus eliminating some of the issues which have been associated with poor outcomes in adolescents (treatment in adult centers, poor compliance, poor enrolment into clinical trials). Thus the differences that we observed in outcome and toxicity are more likely to be related to real differences in the biology of the disease between children and adolescents.

Our results are similar to those reported by the large groups. The optimal treatment for adolescent NHL patients has not yet been established, and the reasons for the inferior outcomes in adolescents are not completely clear. Potential explanations include patient-related factors, disease-related factors and therapeutic strategies. Patient-related factors include psychosocial aspects unique to this age group, like the transition from the dependence of childhood to the autonomy of adulthood, including disagreements with authority figures, confusion about responsibilities, lack of communication, and failure to accurately perceive the severity of their cancer and the risk it poses. All of these factors will negatively affect the quality of cancer care they receive and their chances of survival.

In summary, we confirm the differences reported in the literature between children and adolescents (> 15 years at diagnosis), in particular with respect to better survival and reduced risk of long-term toxicity in children. While our population was homogeneously assessed and treated, differences were often non-statistically significant due to the low numbers. More collaborative research is needed to better define disease-specific age ranges, by analyzing disease-specific biology and patient characteristics.

References:

1. Bollard CM, Lim MS, Gross TG, Committee COGN-HL. Children's Oncology Group's 2013 blueprint for research: non-Hodgkin lymphoma. Pediatric blood & cancer. Jun 2013;60(6):979-984. https://doi.org/10.1002/pbc.24416 PMid:23255391 PMCid:PMC4327936

2. Mann G, Attarbaschi A, Burkhardt B, et al. Clinical characteristics and treatment outcome of infants with non-Hodgkin lymphoma. British journal of haematology. Nov 2007;139(3):443-449. https://doi.org/10.1111/j.1365-2141.2007.06796.x

3. Patte C, Auperin A, Gerrard M, et al. Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients. Blood. Apr 1 2007;109(7):2773-2780. PMid:17132719 PMcid:PMC1852229

4. Burkhardt B, Mueller S, Khaman T, Perkins SL. Current status and future directions of T-lymphoblastic lymphoma in children and adolescents. British journal of haematology. May 2016;173(4):545-559. https://doi.org/10.1111/bjh.14017 PMid:26991119

5. Han JY, Suh JK, Lee SW, Koh KN, Im HJ, Seo JJ. Clinical characteristics and treatment outcomes of children with anaplastic large cell lymphoma: a single center experience. Blood research. Dec 2014;49(4):246-252. https://doi.org/10.5045/br.2014.49.4.246 PMid:25548758 PMCid:PMC4278006

6. Burkhardt B, Oechsle I, Klapper W, et al. Non-Hodgkin's lymphoma in adolescents: experiences in 378 adolescent NHL patients treated according to pediatric NHL-BFM protocols. Leukemia. Jan 2018;32(1):17-24. PMid:29418310 PMCid:PMC5459374

7. Auerbach RM, Bours D, Patte C, et al. Treatment of children with lymphoblastic lymphoma: results of the International Pilot Study for B-Lymphoblastic Lymphoma, 1990 to 1994. Blood. Apr 15 2000;95(8):2446-2451. PMid:10748020 PMCid:PMC1053248

8. Patte C, Auperin A, Hottot I, et al. Risk-adapted chemotherapy plus consolidation autologous stem cell transplantation for advanced-stage childhood T-lineage lymphoblastic lymphoma: a report from the French Children's Leukaemia Study Group. Blood. Nov 21 2002;100(11):3670-3677. PMid:12394831 PMCid:PMC1200914

9. Patte C, Auperin A, Hottot I, et al. Risk-adapted chemotherapy plus consolidation autologous stem cell transplantation for advanced-stage childhood T-lineage lymphoblastic lymphoma: a report from the French Children's Leukaemia Study Group. Blood. Nov 21 2002;100(11):3670-3677. PMid:12394831 PMCid:PMC1200914
37. Pillon M, Di Tullio MT, Garaventa A, et al. Long-term results of the first Italian Association of Pediatric Hematology and Oncology protocol for the treatment of pediatric B-cell non-Hodgkin lymphoma (AIEOP LNH92). Cancer. Jul 15 2004;101(2):385-394. https://doi.org/10.1102/cancer.20382 PMid:15241838

38. Woessmann W, Seidemann K, Mann G, et al. The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: a report of the BFM Group Study NHL-BFM95. Blood. Feb 1 2005;105(3):948-958. https://doi.org/10.1182/blood-2004-03-0973 PMid:15486066

39. Fujita N, Kobayashi R, Takimoto T, Nakagawa A, Ueda K, Horibe K. Results of the Japan Association of Childhood Leukemia Study (JACLS) NHL-98 protocol for the treatment of B-cell non-Hodgkin lymphoma and mature B-cell acute lymphoblastic leukemia in childhood. Leukemia & lymphoma. Feb 2011;52(2):223-229. https://doi.org/10.3109/10428194.2010.537794 PMid:21261497

40. Sandlund JT, Pu CH, Zhou Y, et al. Effective treatment of advanced-stage childhood lymphoblastic lymphoma without prophylactic cranial irradiation: results of St Jude NHL13 study. Leukemia. Jun 2009;23(6):1127-1130. https://doi.org/10.1038/leu.2008.400 PMid:19194463 PMCID:PMC2843413

41. Ducassou S, Ferlay C, Bergeron C, et al. Clinical presentation, evolution, and prognosis of precursor B-cell lymphoblastic lymphoma in trials LMT96, EORTC 58881, and EORTC 58951. British Journal of Haematology. Feb 2011;152(4):441-451. https://doi.org/10.1111/j.1365-2141.2010.08541.x PMid:2120776

42. Kobayashi R, Yamato K, Tanaka F, et al. Retrospective analysis of non-anaplastic peripheral T-cell lymphoma in pediatric patients in Japan. Pediatric Blood & Cancer. Feb 2010;54(2):212-215. PMid:19856396

43. Windsor R, Stiller C, Webb D. Peripheral T-cell lymphoma in childhood: population-based experience in the United Kingdom over 20 years. Pediatric Blood & Cancer. Apr 2008;50(4):784-787. https://doi.org/10.1111/j.1549-0272.2007.00716.x PMid:18022809

44. Le Deley MC, Rosolen A, Williams DM, et al. Vinblastine in children and adolescents with high-risk anaplastic large-cell lymphoma: results of the randomized ALCL-99-vinblastine trial. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. Sep 1 2010;28(25):3987-3993. https://doi.org/10.1200/JCO.2010.28.5999 PMid:20679620

45. Lowe ED, Sposto R, Perkins SL, et al. Intensive chemotherapy for systemic anaplastic large cell lymphoma in children and adolescents: final results of Children's Cancer Group Study 5941. Pediatric Blood & Cancer. Mar 2009;52(3):335-339. https://doi.org/10.1002/pbc.21817 PMid:18985718 PMCID:PMC2769495

46. Pillon M, Mussolin L, Carraro E, Conter V, Aricò M, Vintì L, Garaventa A, Piglione M, Buffardi S, Sala A, Santoro N, Lo Nigro L, Mura R, Tondo A, Casale F, Farruggia P, Pierani P, Cesaro S, d’Amore ES, Basso G. Detection of prognostic factors in children and adolescents with Burkitt and Diffuse Large B-Cell Lymphoma treated with the AIEOP LNH-97 protocol. Br J Haematol. 2016 Nov;175(3):467-47547. https://doi.org/10.1111/bjh.14240 PMid:27392319

47. Wood WA, Lee SJ. Malignant hematologic diseases in adolescents and young adults. Blood. Jun 2 2011;117(22):5803-5815. https://doi.org/10.1182/blood-2010-12-283092 PMid:21398581